Overview

E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck

Status:
Completed

Trial end date:
2017-09-04

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether patients with Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck who receive either E7050 administered with Cetuximab or Cetuximab alone experience greater benefit

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Eisai Inc.

Collaborator:

PharmaBio Development Inc.

Treatments:

Cetuximab